-
UBS raises loan growth estimates for IndusInd Bank for FY22 to 13%, maintains NEUTRAL on the stock
DLF has started to show consistency in key deliverables of pre-sales & de-leveraging, MS says, adding that the co should benefit from the upcoming residential cycle with a deep launch pipeline
Torrent Pharma reported a miss in Q1 with revenue/EBITDA/PAT coming in lower by 8%/6%/14%, Jefferies says, expects co’s US revenue to remain flat until facilities are cleared
59m Indigo reports huge loss of 3174cr in Q1FY22 losses for 6th straight quarter Quarterly Trend in NET LOSS Q4FY21:-873.5cr Q1FY21:-2849cr Q2FY21:-1194cr Q3FY21:-626.6cr Q4FY21:- 1147.2cr Q1FY22:-3174cr
#GLENMARK_LIFE_SCIENCES Wholly Owned Subsidiary of #GlenmarkPharma IPO Opens #Today; Closes 29-July Price Band: Rs 695–720/Sh To Mobilize = Rs 1513 Crores (Fresh Issue = Rs 1060 Crs; OFS = Rs 453 Crs) Lot Size = 20 Shares | 1 Lot = Rs 14,400 | Retail Max Lots = 13
Potential for reversal of provisions in rest of FY22 is key to focus for M&M Fin, Morgan Stanley in its report on the NBFC after Q1 results reported yesterday
CLSA increases VNB margin estimates for SBI Life by 3-7%, co is one of the preferred picks for the brokerage
Kotak Mahindra's headline pre-provisioning operating profit & profit in-line with weak growth netted off by better margin. While slippages spiked, recoveries have picked up meaningfully from June, CLSA says, has an OUTPERFORM rating with target at Rs 1,900/sh
Strong net interest margin for Kotak Mahindra in Q1, slow growth; slippages decline QoQ, Citi lowers FY22 net profit estimate by 3% to incorporate higher operational expenditure
COROMANDEL: 3.38B EST 2.7 B EST COROMANDEL INTERNATIONAL: Q1 REVENUE 36.6B RUPEES VS 32.13B (YOY); 28.56B (QOQ) COROMANDEL INTERNATIONAL: Q1 CONS NET PROFIT 3.38B RUPEES VS 2.51B (YOY); EST 2.73B I 1.56B (QOQ)
KOTAK MAHINDRA BANK: Q1 SL NET PROFIT 16.4B RUPEES VS 12.44B (YOY); EST 16.5B I 16.82B (QOQ) KOTAK MAHINDRA BANK: Q1 GROSS NPA 3.56 VS 3.25% || NET NPA 1.28% VS 1.21% (QOQ)
F&O BAN New in Ban: Keycap digit one IDEA Still in Ban: Keycap digit two CADILAHC Keycap digit three CANBK Keycap digit four NATIONALUM Keycap digit five SUNTV Out of Ban: Right-pointing triangle IBULHSGFIN
ICICI bank review Keycap digit one strong NII growth of 18% Keycap digit two margins beat estimates Keycap digit three asset quality largely stable: GNPA at 5.15% vs 4.96% QOQ
ICICI BANK: Q1 SL NET PROFIT 46.16 B RUPEES VS 26B RUPEES (YOY);44B RUPEES (QOQ)|| EST 47B VS 44B (QOQ)|| Q1 PROVISION 28.51 B RUPEES VS 76B RUPEES (YOY); 28.8 B RUPEES (QOQ) || Q1 INTEREST EARNED 203.8B RUPEES VS 199.2B RUPEES (YOY); 198.4B RUPEES(QOQ)
CROMPTON GREAVES: Q1 CONS NET PROFIT 947M RUPEES VS 748M (YOY); EST 1.2B | PROFIT 2.49B (QOQ) CROMPTON GREAVES: Q1 REVENUE 10.5B RUPEES VS 7.20B (YOY); 15.22B (QOQ)
CLSA upgrades Havells to Outperform from Sell, raises earnings estimates for FY22 by 20% & FY23 by 12%
CLSA maintains Outperform call on ICICI Lombard but trims FY23/24 estimates by 3%
Macquarie maintains Neutral call on Bajaj Auto as it believes headwinds persist in near term
Citi maintains Sell call on Bajaj Auto, reduces earnings estimates by 1-2% over FY22-24
Nomura maintains Buy rating on Bajaj Auto as export outlook is healthy
Connect with us on social media
